These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 30999559)

  • 41. The Current State of Advanced Therapy Medicinal Products in the Czech Republic.
    Kočí Z; Boráň T; Krůpa P; Kubinová Š
    Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regulatory Capture in Pharmaceutical Policy Making: The Case of National Medicine Agencies Related to the EU Falsified Medicines Directive.
    Borup R; Traulsen JM; Kaae S
    Pharmaceut Med; 2019 Jun; 33(3):199-207. PubMed ID: 31933284
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expert Opinion on Three Phage Therapy Related Topics: Bacterial Phage Resistance, Phage Training and Prophages in Bacterial Production Strains.
    Rohde C; Resch G; Pirnay JP; Blasdel BG; Debarbieux L; Gelman D; Górski A; Hazan R; Huys I; Kakabadze E; Łobocka M; Maestri A; Almeida GMF; Makalatia K; Malik DJ; Mašlaňová I; Merabishvili M; Pantucek R; Rose T; Štveráková D; Van Raemdonck H; Verbeken G; Chanishvili N
    Viruses; 2018 Apr; 10(4):. PubMed ID: 29621199
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The pharmaceutical industry as a political player.
    Abraham J
    Lancet; 2002 Nov; 360(9344):1498-502. PubMed ID: 12433532
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Medicinal products in the European Union--between harmonization and divergence.
    Lojko N
    Med Law; 2010 Mar; 29(1):61-76. PubMed ID: 22457998
    [TBL] [Abstract][Full Text] [Related]  

  • 46. China's perspective on similar biotherapeutic products.
    Liang C; Wang J
    Biologicals; 2011 Sep; 39(5):312-6. PubMed ID: 21924622
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Where is industry getting it wrong? A review of quality concerns raised at Day 120 by the Committee For Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products.
    Borg JJ; Robert JL; Wade G; Aislaitner G; Pirozynski M; Abadie E; Salmonson T; Vella Bonanno P
    J Pharm Pharm Sci; 2009; 12(2):181-98. PubMed ID: 19732496
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regulatory issues surrounding nanomedicines: setting the scene for the next generation of nanopharmaceuticals.
    Gaspar R
    Nanomedicine (Lond); 2007 Apr; 2(2):143-7. PubMed ID: 17716116
    [No Abstract]   [Full Text] [Related]  

  • 49. Recent Regulatory Trends in Pharmaceutical Manufacturing and their Impact on the Industry.
    Tabersky D; Woelfle M; Ruess JA; Brem S; Brombacher S
    Chimia (Aarau); 2018 Mar; 72(3):146-150. PubMed ID: 29631666
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quality control in the regulation of pharmaceuticals.
    Maynard A
    Pharmacoeconomics; 2005; 23(5):421-2. PubMed ID: 15896093
    [No Abstract]   [Full Text] [Related]  

  • 51. Drug marketing exclusivity under United States and European Union law.
    Junod V
    Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
    [No Abstract]   [Full Text] [Related]  

  • 52. Fifty years of the European medicines regulatory network: reflections for strengthening intra-regional cooperation in the Region of the Americas.
    Allchurch MH; Barbano DB; Pinheiro MH; Lazdin-Helds J
    Rev Panam Salud Publica; 2016 May; 39(5):288-293. PubMed ID: 27706411
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Proposal for new European pharmaceutical legislation to permit access to custom-made anti-sense oligonucleotide medicinal products.
    Johnston JD; Feldschreiber P
    Br J Clin Pharmacol; 2014 Jun; 77(6):939-46. PubMed ID: 24750439
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of Taiwan's strategies for regulating nanotechnology-based pharmaceuticals harmonized with international considerations.
    Guo JW; Lee YH; Huang HW; Tzou MC; Wang YJ; Tsai JC
    Int J Nanomedicine; 2014; 9():4773-83. PubMed ID: 25342901
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [International approaches to the regulation of cell therapy products].
    Piatigorskaia NV; Tulina MA; Aladysheva ZhI; Beregovykh VV
    Vestn Ross Akad Med Nauk; 2013; (8):4-8. PubMed ID: 24340637
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic bacteriophages as a rescue treatment for drug-resistant infections - an in vivo studies overview.
    Kwiatek M; Parasion S; Nakonieczna A
    J Appl Microbiol; 2020 Apr; 128(4):985-1002. PubMed ID: 31778593
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Towards Inhaled Phage Therapy in Western Europe.
    Wienhold SM; Lienau J; Witzenrath M
    Viruses; 2019 Mar; 11(3):. PubMed ID: 30909579
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Environmental risk assessment of veterinary medicinal products in the EU--a regulatory perspective.
    Koschorreck J; Koch C; Rönnefahrt I
    Toxicol Lett; 2002 May; 131(1-2):117-24. PubMed ID: 11988364
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Delivering Phage Products to Combat Antibiotic Resistance in Developing Countries: Lessons Learned from the HIV/AIDS Epidemic in Africa.
    Nagel TE
    Viruses; 2018 Jun; 10(7):. PubMed ID: 29954053
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Protecting the rights of producers original medicines.
    Pashkov V; Kotvitska A; Noha P
    Wiad Lek; 2017; 70(4):834-837. PubMed ID: 29064813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.